Why the study?
How do aspirin and P2Y12 inhibitors impact platelet-mediated activation of neutrophils and monocytes across various diseases?
How do aspirin and P2Y12 inhibitors impact platelet-mediated activation of neutrophils and monocytes across various diseases?
This review highlights that antiplatelet therapies like aspirin and P2Y12 inhibitors not only prevent thrombosis but also significantly modulate immune responses by attenuating platelet-leukocyte interactions.
No takes yet. Share an insight, caveat, or question.
May alter immune responses variably by disease; leaves open disease-specific antiplatelet strategies.
Schrottmaier et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: